Results 41 to 50 of about 5,151 (175)

Progressive multifocal leukoencephalopathy selectively affecting Broca's and Wernicke's areas in an immunocompetent patient: A case report

open access: yesRadiology Case Reports, 2023
Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal, demyelinating disease of the central nervous system. The disease almost exclusively presents in immunosuppressed patients, such as those with acquired immunodeficiency syndrome, a ...
Renaid B. Kim, BS   +2 more
doaj   +1 more source

A case of Progressive Multifocal Leukoencephalopathy in a HIV patient

open access: yesJournal of Clinical and Biomedical Sciences, 2022
Progressive Multifocal Leukoencephalopathy is a demyelinating disease of the brain which occurs as a result of reactivation of JC (John Cunningham) virus.
. Aashish   +5 more
doaj   +1 more source

First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

open access: yesHemaSphere, Volume 10, Issue 8, August 2026.
Abstract First‐line (1L) bendamustine plus rituximab (BR) leads to high response rates in follicular lymphoma (FL), but maintaining durable remissions remains challenging. We report the 3‐year follow‐up from arm 3 of the phase 1b/2 EPCORE NHL‐2 trial (NCT04663347) of epcoritamab, a subcutaneously administered CD3×CD20 bispecific antibody, combined with
Umberto Vitolo   +21 more
wiley   +1 more source

Progressive Multifocal Leukoencephalopathy (PML) – a Case Report.

open access: yesPulse, 2014
Progressive Multifocal Leukoencephalopathy (PML) is a rare and usually fatal viral disease occurring almost exclusively in people with severe immune deficiency. This is a demyelinating disease of the central nervous system (CNS) that usually leads to death or severe disability.
BS Khan, J Alam
openaire   +2 more sources

The pivotal image findings of progressive multifocal leukoencephalopathy: A case report

open access: yesTungs’ Medical Journal
Progressive multifocal leukoencephalopathy (PML) is a rare disease associated with the reactivation of the JC virus, particularly in immunocompromised patients.
Shou-De Ma   +4 more
doaj   +1 more source

Progressive multifocal leukoencephalopathy in the clinical practice of a neurologist. Case report [PDF]

open access: yesConsilium Medicum
Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection with severe brain damage caused by the JC-virus, against the background of immunosuppressive conditions.
Yuliana A. Belova, Sergey V. Kotov
doaj   +1 more source

Safety, Pharmacokinetics, Food effect, and Pharmacodynamics of AJM347, a Selective α4β7 Integrin Antagonist: A First‐in‐Human Single‐ and Multiple‐Ascending Dose Study in Healthy Male Volunteers

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract This first‐in‐human study evaluated the safety, pharmacokinetics (PK), food effect, and pharmacodynamics (PD) of AJM347, a novel orally active, selective α4β7 integrin antagonist, in healthy Caucasian and Japanese adult males. The study consisted of three parts.
Tetsuya Koyama, Tatsunori Seki
wiley   +1 more source

Progressive multifocal leukoencephalopathy in HIV-infected patients: clinical features and diagnosis (literature review)

open access: yesЖурнал инфектологии, 2019
Progressive multifocal leukoencephalopathy (PML) is one of the most severe opportunistic diseases of the central nervous system, which leads to multiple demyelination of brain structures, neurological symptoms and frequent death or disability of the ...
E. A. Samotolkina   +3 more
doaj   +1 more source

AIDS-related progressive multifocal leukoencephalopathy

open access: yesRevista da Sociedade Brasileira de Medicina Tropical, 2020
INTRODUCTION: Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by reactivation of JC virus (JCV).
Carolina de Oliveira Abrão   +5 more
doaj   +1 more source

Safety and Effectiveness of Dimethyl Fumarate in Japanese Patients With Multiple Sclerosis: Subgroup Analysis of Older Patients and Patients Switching From Fingolimod or Natalizumab Using 2‐Year Post‐Marketing Surveillance Data

open access: yesClinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
In a 2‐year post‐marketing surveillance of Japanese patients with multiple sclerosis, dimethyl fumarate (DMF) showed manageable safety, with no new concerns identified; lymphocyte decreases were more frequent in older patients and those switching from fingolimod.
Ichiro Nakashima   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy